U.S. Physical Therapy’s first quarter results were met with a sharp negative market reaction, reflecting investor concerns over margin compression and profit performance. Management attributed the quarter's margin decline primarily to severe winter weather, which led to over 31,000 lost patient visits and higher fixed costs, as well as upfront investments in new initiatives. CEO Christopher J. Reading acknowledged that, despite robust demand and higher commercial reimbursement rates, these headwinds weighed on profitability, stating, “We lost over 31,000 visits to weather, which impacts not just revenue, but means that many of our highest paid people we have to pay to sit at home during these events, which has a drag on margins.”
Is now the time to buy USPH? Find out in our full research report (it’s free for active Edge members).
U.S. Physical Therapy (USPH) Q1 CY2026 Highlights:
- Revenue: $198.3 million vs analyst estimates of $198.2 million (7.9% year-on-year growth, in line)
- Adjusted EPS: $0.46 vs analyst expectations of $0.52 (11% miss)
- Adjusted EBITDA: $20.24 million vs analyst estimates of $21.81 million (10.2% margin, 7.2% miss)
- EBITDA guidance for the full year is $104 million at the midpoint, in line with analyst expectations
- Operating Margin: 6.3%, down from 10.7% in the same quarter last year
- Sales Volumes were flat year on year (13.9% in the same quarter last year)
- Market Capitalization: $926.1 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From U.S. Physical Therapy’s Q1 Earnings Call
- Joanna Sylvia Gajuk (Bank of America) asked about bridging Q1 performance to full-year EBITDA guidance. CEO Christopher J. Reading stressed that Q1 was in line with expectations, attributing margin drag to weather and affirming that hospital partnership ramp-up and acquisitions were already factored into guidance.
- Jeff (Jefferies) inquired about elevated expenses in rent, supplies, and corporate lines. CFO Jason Curtis explained that upfront investments in 2026 initiatives and weather-related fixed cost deleverage contributed to the increase, but expected normalization as volumes rise.
- Jeff (Jefferies) also sought clarity on the cadence of hospital partnerships and M&A activity. Reading indicated confidence in more hospital deals but cautioned that timing is unpredictable due to complex negotiations with large institutions.
- Lawrence Scott Solow (CJS Securities) asked about the long-term volume growth potential from hospital alliances. Reading noted strong interest and suggested that large-scale partnerships similar to NYU could become a significant growth driver over the next three to five years.
- Constantine Davides (Citizens) requested details on the cash-based program initiative. President Eric Joseph Williams described rapid partner adoption of laser, shockwave, and dry needling services, with notable patient interest and growing clinician participation.
Catalysts in Upcoming Quarters
The StockStory team will be watching (1) the pace of clinic transitions and patient volume growth from new hospital partnerships, (2) the tangible impact of AI-driven documentation and other technology initiatives on operating margins, and (3) the expansion and uptake of cash-based programs across the clinic network. Progress on M&A and further partnership announcements will also serve as key indicators of strategy execution.
U.S. Physical Therapy currently trades at $60.84, down from $73.65 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
